[go: up one dir, main page]

DK2215119T3 - Monoklonale antistoffer der binder til HGM-CSF og medicinske sammensætninger omfattende de samme. - Google Patents

Monoklonale antistoffer der binder til HGM-CSF og medicinske sammensætninger omfattende de samme.

Info

Publication number
DK2215119T3
DK2215119T3 DK08848696.4T DK08848696T DK2215119T3 DK 2215119 T3 DK2215119 T3 DK 2215119T3 DK 08848696 T DK08848696 T DK 08848696T DK 2215119 T3 DK2215119 T3 DK 2215119T3
Authority
DK
Denmark
Prior art keywords
hgm
csf
bind
same
monoclonal antibodies
Prior art date
Application number
DK08848696.4T
Other languages
English (en)
Inventor
Kenzo Takada
Kantou Nakajima
Barbara Kistler
John Park
Original Assignee
Evec Inc
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evec Inc, Boehringer Ingelheim Int filed Critical Evec Inc
Application granted granted Critical
Publication of DK2215119T3 publication Critical patent/DK2215119T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK08848696.4T 2007-11-13 2008-11-12 Monoklonale antistoffer der binder til HGM-CSF og medicinske sammensætninger omfattende de samme. DK2215119T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007294945 2007-11-13
JP2008052471 2008-02-14
PCT/US2008/012680 WO2009064399A1 (en) 2007-11-13 2008-11-12 Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same

Publications (1)

Publication Number Publication Date
DK2215119T3 true DK2215119T3 (da) 2013-02-04

Family

ID=40329216

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08848696.4T DK2215119T3 (da) 2007-11-13 2008-11-12 Monoklonale antistoffer der binder til HGM-CSF og medicinske sammensætninger omfattende de samme.

Country Status (31)

Country Link
US (2) US8679502B2 (da)
EP (3) EP2215119B1 (da)
KR (1) KR20100102108A (da)
CN (2) CN104072613A (da)
AR (1) AR069290A1 (da)
AU (1) AU2008321429A1 (da)
BR (1) BRPI0820530A2 (da)
CA (1) CA2705539A1 (da)
CL (1) CL2008003361A1 (da)
CO (1) CO6382188A2 (da)
DK (1) DK2215119T3 (da)
EC (1) ECSP10010251A (da)
ES (1) ES2401536T3 (da)
HR (1) HRP20130204T1 (da)
IL (1) IL205576A0 (da)
MA (1) MA31899B1 (da)
ME (1) ME01005B (da)
MX (1) MX2010005291A (da)
NZ (2) NZ586027A (da)
PE (1) PE20091420A1 (da)
PL (1) PL2215119T3 (da)
PT (1) PT2215119E (da)
RS (1) RS52713B (da)
RU (2) RU2517596C2 (da)
SG (1) SG176499A1 (da)
SI (1) SI2215119T1 (da)
TN (1) TN2010000210A1 (da)
TW (2) TWI434854B (da)
UY (1) UY31466A1 (da)
WO (1) WO2009064399A1 (da)
ZA (1) ZA201003467B (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
WO2008141391A1 (en) * 2007-05-23 2008-11-27 Crc For Asthma And Airways Ltd Neutralizing antibodies
WO2009062238A1 (en) * 2007-11-12 2009-05-22 Crc For Asthma And Airways Ltd Epitope for neutralizing antibodies
CN104072613A (zh) 2007-11-13 2014-10-01 Evec股份有限公司 与hGM-CSF结合的单克隆抗体及包含它的药物组合物
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
MX2011002558A (es) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
AU2009329814B2 (en) 2008-12-22 2015-06-18 The University Of Melbourne Osteoarthritis treatment
WO2010071923A1 (en) 2008-12-22 2010-07-01 The University Of Melbourne Pain treatment
CN106975074A (zh) 2010-06-24 2017-07-25 勃林格殷格翰国际有限公司 糖尿病治疗
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
RU2013156435A (ru) 2011-07-06 2015-08-20 МорфоСис АГ Терапевтические комбинации анти-cd20 и анти-gm-csf антител и их применения
CN109999195A (zh) 2012-09-20 2019-07-12 莫弗系统股份公司 类风湿关节炎的治疗
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
JP6339578B2 (ja) 2012-10-31 2018-06-06 タケダ・ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ Ｇｍ−ｃｓｆ中和化合物を含む凍結乾燥製剤
WO2014138862A1 (en) * 2013-03-14 2014-09-18 John Schrader Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof
CN105705518A (zh) 2013-08-30 2016-06-22 塔科达有限责任公司 用于治疗类风湿性关节炎或作为镇痛药的中和gm-csf的抗体
EP3139960B1 (en) 2014-05-07 2024-01-17 Takeda Pharmaceutical Company Limited Liquid formulation comprising gm-csf neutralizing compound
EP3368561B1 (en) * 2015-10-30 2025-09-17 Medimmune Limited Prevention of n-terminal truncation in igg light chains
JP7256116B2 (ja) 2016-09-19 2023-04-11 アイ－エムエービー バイオファーマ （ハンジョウ） カンパニー リミテッド 抗ｇｍ－ｃｓｆ抗体およびその使用
CN116948035A (zh) * 2017-06-25 2023-10-27 西雅图免疫公司 多特异性抗体及其制备和使用方法
KR102845020B1 (ko) * 2017-12-28 2025-08-12 난징 레전드 바이오테크 씨오., 엘티디. Pd-l1에 대한 항체 및 변이체
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
EP3623382A1 (en) * 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
BR112021015519A2 (pt) 2019-02-08 2022-01-11 Lubrizol Advanced Mat Inc Composto, combinação de um composto, composição, uso de um composto, e, método de tratamento e/ou cuidado cosmético não terapêutico da pele, cabelo, unhas e/ou membranas mucosas
WO2025221669A1 (en) * 2024-04-18 2025-10-23 Promab Biotechnologies, Inc. Fusion protein comprising il-12 and gm-csf
CN120399067B (zh) * 2025-07-02 2025-09-30 武汉伊莱瑞特生物科技股份有限公司 一种与人gm-csf特异性结合的单克隆抗体及其检测试剂盒和应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8624899D0 (en) * 1986-10-17 1986-11-19 Sandoz Ltd Monoclonal antibodies
JPH03502582A (ja) * 1988-05-31 1991-06-13 シェリング・バイオテック・コーポレーション 骨髄性白血病の治療方法
PH27534A (en) 1989-07-14 1993-08-18 Schering Corp Antoganists of gm-csf derived from the carboxyl terminus
GB8925590D0 (en) * 1989-11-13 1990-01-04 Central Blood Lab Authority Monoclonal antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
WO1992008474A2 (en) 1990-11-20 1992-05-29 The National Heart & Lung Institute Treatment of lung diseases
CA2060741A1 (en) 1991-02-11 1992-08-12 Robert S. Greenfield Gm-csf inhibiting oligopeptides
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US5989830A (en) * 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
US5662138A (en) 1996-06-12 1997-09-02 Wang; Wen-Hsing Drop head structure
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
MXPA02012434A (es) 2000-06-16 2004-09-06 Cambridge Antibody Tech Anticuerpos que se unen inmunoespecificamente a estimulador de linfocitos ii.
EP1409530A2 (en) 2000-09-19 2004-04-21 Microbia, Inc. Modulation of secondary metabolite production by zinc binuclear cluster proteins
PE20021080A1 (es) 2001-04-12 2003-02-12 Boehringer Ingelheim Int Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
WO2003040341A2 (en) 2001-11-07 2003-05-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-hepatitis a virus antibodies
US7381801B2 (en) * 2002-02-13 2008-06-03 Ludwig Institute For Cancer Research Chimerized GM-CSF antibodies
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
BRPI0417342A (pt) 2003-12-03 2007-04-17 Neose Technologies Inc fator estimulante de colÈnia de granulócitos glicopeguilado
UA89364C2 (en) 2003-12-03 2010-01-25 Биодженерикс Аг Granulocyte colony stimulating factor peptide conjugate (g-csf)
DE602004021773D1 (de) 2004-05-05 2009-08-13 Micromet Ag Herstellung eines einkettigen fv Antikörperfragments
WO2006011353A1 (ja) 2004-07-30 2006-02-02 Thk Co., Ltd. ねじ溝加工方法
UA94403C2 (ru) * 2005-04-18 2011-05-10 Микромет Аг Человеческое моноклональное антитело, которое нейтрализует gm-csf
SI3620171T1 (sl) * 2005-05-18 2022-09-30 Morphosys Ag Protitelesa proti GM-CSF in uporabe zanje
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
WO2007092939A2 (en) * 2006-02-08 2007-08-16 Morphotek, Inc. Antigenic gm-csf peptides and antibodies to gm-csf
US8398972B2 (en) 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
EP2402013A1 (en) 2006-11-21 2012-01-04 Kalobios Pharmaceuticals, Inc. Methods of Treating Chronic Inflammatory Diseases using a GM-CSF Antagonist
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
CN104072613A (zh) 2007-11-13 2014-10-01 Evec股份有限公司 与hGM-CSF结合的单克隆抗体及包含它的药物组合物

Also Published As

Publication number Publication date
BRPI0820530A2 (pt) 2015-06-16
CN101970489A (zh) 2011-02-09
ES2401536T3 (es) 2013-04-22
TWI434854B (zh) 2014-04-21
WO2009064399A1 (en) 2009-05-22
SG176499A1 (en) 2011-12-29
EP2535353A8 (en) 2013-04-03
CO6382188A2 (es) 2012-02-15
AU2008321429A1 (en) 2009-05-22
HK1146729A1 (en) 2011-07-08
AR069290A1 (es) 2010-01-13
MA31899B1 (fr) 2010-12-01
NZ586027A (en) 2012-01-12
RU2010123693A (ru) 2011-12-20
EP2215119A1 (en) 2010-08-11
TW201206955A (en) 2012-02-16
MX2010005291A (es) 2010-11-12
CA2705539A1 (en) 2009-05-22
SI2215119T1 (sl) 2013-04-30
PL2215119T3 (pl) 2013-06-28
IL205576A0 (en) 2010-11-30
US20140205611A1 (en) 2014-07-24
ME01005B (me) 2012-10-20
ZA201003467B (en) 2012-01-25
CN101970489B (zh) 2014-06-11
HRP20130204T1 (hr) 2013-04-30
PE20091420A1 (es) 2009-10-17
EP2215119B1 (en) 2012-12-26
PT2215119E (pt) 2013-02-11
RU2517596C2 (ru) 2014-05-27
NZ597023A (en) 2013-07-26
US8679502B2 (en) 2014-03-25
KR20100102108A (ko) 2010-09-20
UY31466A1 (es) 2009-07-17
CN104072613A (zh) 2014-10-01
RU2013141223A (ru) 2015-03-20
US20110182905A1 (en) 2011-07-28
CL2008003361A1 (es) 2010-02-05
ECSP10010251A (es) 2010-08-31
EP2559706A1 (en) 2013-02-20
RS52713B (sr) 2013-08-30
EP2535353A1 (en) 2012-12-19
TN2010000210A1 (en) 2011-11-11
TW200927760A (en) 2009-07-01

Similar Documents

Publication Publication Date Title
DK2215119T3 (da) Monoklonale antistoffer der binder til HGM-CSF og medicinske sammensætninger omfattende de samme.
CY2019004I1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
DK3184546T3 (da) Antistoffer, der binder human cgrp-receptor
IL205545A0 (en) Monoclonal antibody capable of binding to anexelekto, and use thereof
DK2185574T3 (da) Antistoffer og relaterede molekyler, der bindes til 24P4C12-proteiner
IL211284A0 (en) Antibodies binding ccr2, compositions comprising the same and uses thereof
DK3360571T3 (da) Antistoffer, der binder til et intracellulært PRL-1- eller PRL-3-polypeptid
BRPI0807991A2 (pt) Anticorpos anti-il-23r elaborados.
FI20070853A0 (fi) Glykaania sitovat monoklonaaliset vasta-aineet
IL204615A0 (en) Human antibodies that bind mesothelin, and uses thereof
BRPI0817250A2 (pt) Anticorpo anti-receptor da il-6.
IL234081B (en) Antibody binds cd3–epsilon in different species
IL186486A0 (en) Antibodies which bind to gm-csf and pharmaceutical compositions containing the same
IL205127A (en) Antibody to aβ is humanized, a preparation containing it and its uses
BRPI0914763A2 (pt) composição aglutinante
DK2132230T3 (da) Apoptotiske anti-ige-antistoffer, der binder det membranbundne ige
LT3339445T (lt) Baltymai, suryšantys interleukiną 13
IL201340A (en) Antidote 3dc - epsilon in various species
BRPI0815075A2 (pt) Aglutinantes
IL198592A0 (en) Tes7 and antibodies that bind thereto
HUE038501T2 (hu) Antitest készítmények
IL197831A (en) Human antibodies that bind 4cxcr, preparations containing them and their uses
IL221205A0 (en) Antibody drug conjugates (adc) that bind to 161p2f10b proteins, compositions comprising the same and uses thereof
SI2510011T1 (sl) Monoklonska protitelesa, ki veĹľejo B7H6 in njihova uporaba
BRPI0814111A2 (pt) Anticorpo monoclonal citotóxico anticâncer